Background: Nocardia are uncommon pathogens that disproportionately afflict the immunocompromised host. Epidemiology and outcome data of Nocardia infections in transplant recipients are limited.
| INTRODUC TI ON
Nocardia are ubiquitous aerobic gram-positive, partially acid-fast bacilli that can cause localized or disseminated disease, most commonly affecting the lungs, skin and brain. 1 They can be found worldwide but some species are more prevalent in specific geographic areas. Transmission most commonly occurs via inhalation or direct inoculation through the skin. 2 Nocardia are uncommon pathogens that disproportionately afflict immunocompromised hosts. Nocardiosis has been described by some as an emerging infectious disease possibly driven by increases in the number of immunocompromised individuals. 3 However, it is unclear whether Nocardia incidence is increasing in the transplant population, as some centers report an overall decline in the incidence of Nocardia in comparison to historical data. 4 Previously published data from our center demonstrated an increase in Nocardia infections in immunocompetent patients with non-cystic fibrosisrelated bronchiectasis and stable to declining Nocardia infections in immunocompromised transplant patients. 5 Epidemiologic and outcome data describing Nocardia infections in the solid organ (SOT) and hematopoietic cell transplant (HCT)
populations remain limited 4, [6] [7] [8] [9] [10] [11] [12] and many questions exist regarding optimal management. We performed a retrospective review of all SOT and HCT recipients with nocardiosis over an 18-year period at a large academic transplant center to further characterize the presentation, treatment and outcome in this population.
| PATIENTS AND ME THODS

| Study design
This was a single center, retrospective cohort study of patients seen at Duke University Medical Center, a tertiary care academic center.
Duke is an active transplant center with 1660, 1264, 736, 827, 21
and 4584 kidney, lung, liver, heart, heart-lung, and HCT transplanted patients, respectively, during the study period. The study was approved by the Duke University Health System Institutional Review
Board for Clinical Investigation (Pro00049544).
| Data extraction
As described in a previously published retrospective cohort study, 5 an institutional tool called DEDUCE was used to identify all patients with at least one positive culture for Nocardia over an 18-year period from January 1st, 1996 through December 31st, 2013. 13 The present study includes a subset of that cohort of patients with a history of either SOT or HCT prior to the positive Nocardia culture. Microbiology and survival data were obtained directly from the DEDUCE system.
Patient survival for patients not known to have died during the study period was censored at the date of the last clinic visit within the health care system or at December 31, 2013, whichever came first.
All patients who underwent transplantation during the study period were utilized for the incidence calculations. The "at-risk" population was determined utilizing DEDUCE to ascertain the latest encounter in the medical system. Clinical data including baseline demographics, underlying disease, transplant status, immunosuppression (including that applied in the presence of rejection or graft-versus host dis- 
| Microbiology
Nocardia were isolated from specimens sent for bacterial, fungal, 
| Definitions
Nocardia infection was defined as at least one positive culture from a patient specimen. 
| Statistical analysis
Descriptive statistics were used to summarize the basic findings. 
| RE SULTS
In total, 51 transplant recipients with Nocardia infection were identified during the 18-year study period, including 14 HCT and 37 SOT recipients. One patient with a remote history of HCT followed by primary lung transplant and ultimate redo lung transplant was in- The primary species of Nocardia isolated was Nocardia nova complex, which was found in 39.2% (n = 20) of the patients, followed by Nocardia asteroides complex in 35.3% (n = 18) and Nocardia farcinica in 5.9% (n = 3). Available antibiotic susceptibilities for Nocardia isolates at our center during this study period have been recently published. 5 In this cohort, Nocardia antimicrobial susceptibility testing was not performed on all isolates; however, this testing was available in 86% (n = 12) and 78% (n = 29) of HCT and SOT cases, respectively.
Overall, Nocardia spp isolated from transplant patients were highly susceptible to trimethoprim-sulfamethoxazole (TMP-SMX) (98%) as well as other agents, including linezolid (100%), amikacin (99%), imipenem (78%), and clarithromycin (71%).
Changes in treatment regimens were common. Twenty-five percent (n = 13) received 2 regimens, 14% (n = 7) received 3 regimens and 16% (n = 8) 4 or 5 different regimens.
Median length of follow-up after Nocardia diagnosis was 405 days (IQR 64-2350 days) in the SOT group with a total of 50 523
person-days of follow-up and 89 days (IQR 24.3-727 days) in the HCT group with a total of 11 523 patient-days of follow up.
| HCT population
Nocardia infection was identified in 14 patients among 4584 HCT recipients during the study period. Baseline characteristics of the HCT recipients are shown in Table 1 . In general, HCT patients were younger than their SOT counterpart (Table 2 ) with a median age of 38 years (range 1-68 years) and were predominantly male. The majority (93%, n = 13) had undergone allogeneic HCT and received a non-myeloablative regimen (71%, n = 10), most commonly consisting of alemtuzumab, melphalan, and fludarabine. Four patients (29%) were receiving TMP-SMX prophylaxis at the time of Nocardia diagnosis. This was a highly immunosuppressed HCT population with 36% (n = 5) having undergone at least one prior HCT before the current HCT (either autologous or allogeneic) and 93% (n = 13)
with GVHD at the time of Nocardia diagnosis. Skin GVHD was most common (85%, n = 11) followed by GI tract (69%, n = 9) and liver (38%, n = 5) involvement with 69% (n = 9) having more than one site involved. Data on management of GVHD was available for 12/13 patients and consisted of at least one agent (range 1-4 agents), Underlying disease n (%)
Acute myelogenous leukemia 1
Chronic lymphocytic leukemia 1
Chronic myelogenous leukemia 1 (7)
Hodgkin lymphoma 4 (29)
Non-Hodgkin lymphoma 1
Myelodysplastic syndrome 1
Multiple myeloma 1 (7) Other (PNH, WAS) 2 (14)
Donor source n (%)
Matched related donor 5 (36)
Matched unrelated donor 7 (50)
Umbilical cord donor 1
Conditioning regimen n (%)
Myeloablative 4 (29)
Non-myeloablative 10 (71) HCT, hematopoietic cell transplant; PNH, paroxysmal nocturnal hemoglobinuria; WAS, Wiskott Aldrich Syndrome.
including corticosteroids (100%, n = 12, median daily prednisone dose equivalent of 35 mg [IQR 22.5-48.8 mg]), calcineurin inhibitors 86% (n = 10 tacrolimus or cyclosporine), and mycophenolate (75%; n = 9). One patient (7.1%) had received rituximab and 50% (n = 7) had received alemtuzumab in the year prior to Nocardia diagnosis. One patient (7.1%) had received basiliximab in the preceding 6 months.
Characteristics of Nocardia infection in the HCT population are shown in Table 3 . Infection occurred a median of 153 days (IQR 134-359 days) following transplantation with the diagnosis made most often within a month of symptom onset. Invasive tests were often utilized to make the diagnosis of Nocardia infection, most commonly bronchoscopy, which was performed in 50% (n = 7) of patients.
Pulmonary infection predominated (71%, n = 10) though disseminated infection was common (50%, n = 7), including 6 cases (42.8%) with bacteremia. N. nova complex was the most common species. Of the 12 isolates tested in this group, only one isolate was resistant to TMP-SMX. CMV infection was present in 50% (n = 7) with only one patient having CMV disease.
The most common initial antibiotic applied was TMP-SMX (93%, n = 13), followed by carbapenems (21%, n = 3) and amikacin (14%, n = 2). Fifty-seven percent (n = 8) of treated HCT patients received monotherapy. Treatment was modified due to either intolerance or disease progression in 21% (n = 3) and 14% (n = 2) of patients, respectively. In patients who were cured (n = 4, 29%), median duration of treatment was 289 days (IQR 240-339 days). Only one patient (25%) was placed on secondary prophylaxis following completion of therapy.
Treatment outcomes were overall poor ( Figure 2 ). Seventy-one percent of patients (n = 10) died prior to completion of Nocardia-directed therapy, with 50% (n = 7) of the patients dying within 3 months of Nocardia infection. Of those cured of infection no relapse was identified.
| SOT population
Nocardia infection was identified in 37 SOT patients during the study period. Baseline demographics are shown in Table 2 .
Immunosuppression regimens in SOT recipients consisted of prednisone (97%, n = 36), tacrolimus (78%, n = 29), cyclosporine (19%, n = 7), and mycophenolate mofetil or azathioprine (68%, n = 25). The median daily prednisone dose at time of diagnosis of the Nocardia infection was 10 mg (IQR 7.5-20 mg).
Eleven percent of patients (n = 4) had received basiliximab in the preceding 6 months. Five percent of patients (n = 2) had received alemtuzumab and one patient (3%) had received muromonab-CD3 in the preceding 12 months. Rejection was seen in 24% (n = 9) of the patients in the preceding 6-months. CMV infection was present in 24%
(n = 9) of the SOT patients, however, only one patient had CMV disease.
Characteristics of Nocardia infection in the SOT population are shown in Table 3 . Infection occurred a median of 370 days (IQR 141-885 days) following transplantation with the diagnosis made after a longer symptomatic period when compared to the HCT group.
Similar to HCT, bronchoscopic evaluation was the primary diagnostic procedure; lung involvement predominated in the SOT group but disseminated disease was common (27%, n = 10), including 6 (16.2%) cases with bacteremia, albeit less common than in the HCT group.
N. nova complex also predominated in SOT recipients.
The most common initial antibiotic applied was TMP-SMX (81%, n = 30) followed in frequency by a carbapenem (38%, n = 14).
Monotherapy was used in 43% (n = 16). Treatment was modified due to either intolerance or disease progression in 16% (n = 6) and 3%
(n = 1) of patients, respectively. Of the 29 Nocardia isolates tested, none were resistant to TMP-SMX. Nocardia infections were treated a median duration of 348 days (IQR 234-391 days) and 60% (n = 15) of patients were placed on secondary prophylaxis following completion of therapy. TMP-SMX was the most commonly employed agent for prophylaxis although 2 patients (5%) received azithromycin due to allergy or intolerance of TMP-SMX. Treatment outcomes were better in the SOT than the HCT group with 52% (n = 19) of SOT recipients cured, 32% (n = 12) dying prior to completion of Nocardiadirected therapy and 2 patients (5%) with relapsed disease. Patients with heart transplants had significantly better survival than all other groups (P = .00064) (Figure 2 ).
| D ISCUSS I ON
We report 51 cases of Nocardia infection occurring in 14 HCT and 37
SOT recipients diagnosed at a single tertiary transplant center over an alongside a single center retrospective case-control study in SOT patients in the United States 11 and a more contemporary multicenter case-control study in SOT patients in Europe. 10, 12 This study adds to the limited data that exists regarding nocardiosis following transplant.
Despite an overall increase in the immunocompromised population over time and concerns that Nocardia represents an emerging pathogen in transplantation, 3 we did not see significant increases in the incidence across time in our SOT or HCT groups. There were no reported Nocardia infections in our pancreas, intestinal or multivisceral transplant populations. Moreover, consistent with other centers [16] [17] [18] , we found a trend toward a decrease in the incidence among the heart transplant population from 28/1000 patients in the 1996-2001 time period to 7.5/1000 patients in 2008-2013. Though not statistically significant, the incidence of nocardiosis in the lung transplant population increased overall from the earliest time period aligning with more recent data from other centers wherein nocardiosis has been reported most commonly in this SOT group.
11,19
HCT n(%) n = 14 SOT n(%) n = 37 (14) 4 (11) Other open biopsy 2 (14) 4 (11) Radiographically guided needle biopsy 1 (7) 5 (14) Skin biopsy 1 (7) 2 (5) Sputum culture 0 6 (16)
Cytomegalovirus (CMV)
CMV infection 7 (50) 9 (24) CMV disease 1 (7) 1 (3)
HCT, hematopoietic cell transplant; SOT, solid organ transplant.
TA B L E 3 Clinical characteristics of
Nocardia infection in HCT and SOT recipients F I G U R E 2 Kaplan-Meier one-year survival curve after Nocardia infection diagnosis among transplant recipients. Tx, transplant; HSCT, hematopoietic cell transplant. Global differences among represented subgroups (P = .005). Survival difference between heart transplant recipients and all other subgroups (P = .00064) When considering long-term management of these patients, secondary prophylaxis is often employed in those with ongoing immunosuppression due to the concern for recurrent infection. 8, 20, 21, 25 Delineating the most appropriate secondary prophylactic agent and dose may become more important if further data support shorter courses of primary therapy. In our series, secondary prophylaxis was prescribed in 31% of patients, most commonly with TMP-SMX. No standard approach to prophylactic dosing was observed, with doses ranging from 80 mg of the TMP component three times a week to 240 mg per day in patients with varying weight and renal function.
Two patients in our series were prescribed azithromycin for secondary prophylaxis in isolates deemed susceptible to clarithromycin;
neither of these patients developed a Nocardia relapse. Data regarding the use of azithromycin for the management of Nocardia is overall limited but warrants consideration given poor tolerability of TMP-SMX in this population.
Relapse of Nocardia infection was found in two patients in our cohort, one with prior lung transplant and the second with prior heart transplant. Neither received short-course antibiotic therapy.
One relapse occurred off TMP-SMX prophylaxis, as the patient had reportedly been intolerant to sulfa drugs and presented with disseminated Nocardia infection. After treatment of the relapse, secondary prophylaxis was continued with no further recurrence of Nocardia infection. Data on secondary prophylaxis are not available on the second patient that relapsed. This patient developed chronic rejection and died 2 years after the relapsed Nocardia infection.
Overall, outcomes were poor in this series. Within the SOT group, 57% were cured compared to 89% in a comparable US-based single center study. 11 Among the SOT groups, heart transplant recipients had a significantly better overall survival (P < .05) than any of the other subgroups (Figure 2) . Consistent with the literature and our series, historically, heart transplants have had a higher incidence of Nocardia infection. This trend has improved over time, in part, due to advances in immunosuppressive regimens applied. 16, 18 It is unclear why improvements in immunosuppressive regimens for heart transplant recipients would confer differential benefit compared to other SOT groups with presumably equal access to these improvements. A change in prophylactic practices in the heart transplant population across time may have also contributed to this trend; however, this was not directly evaluated in this study. Cure rates were particularly low in the HCT subgroup with only 29% of HCT patients cured of infection. These rates are worse compared to outcomes reported by 
| Limitations
Limitations of this study are the retrospective and single center design including the inability to capture all Nocardia infections occurring outside of our institution. Also, patients transplanted prior to the study period were not included in the "at-risk" population when evaluating the incidence of infection across time and may have impacted these results. In addition, molecular species identi- 
| CON CLUS ION
In conclusion, we present the epidemiology and outcome of Nocardia Clinicians should maintain a high degree of suspicion for this pathogen that usually presents months to years after transplant given the potential for severe infection necessitating specific antimicrobial therapy and management. Further study of risk factors for Nocardia infection in transplant patients and the optimal management strategies, including primary and secondary prophylaxis would be valuable.
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